Citalopram, identified in the selected label as Celexa oral tablets, is indicated for major depressive disorder in adults. The label highlights heart electrical-timing risks, important interactions, and other adverse effects. These product facts explain cautions, but cannot determine whether the medicine suits you or caused a particular symptom.
Reading medication warnings can feel unsettling, especially when familiar effects such as nausea appear alongside potentially life-threatening conditions. This article separates those concerns using the supplied FDA labeling record for Celexa tablets containing citalopram hydrobromide, application NDA020822. It does not describe every citalopram product or claim this record is the newest available version. The main focus is the label’s particular heart-rhythm warning and the factors that can increase exposure to the medicine. Other safety information provides context, without offering a prescription decision, medication-change instructions, or a way to diagnose symptoms at home.
What is citalopram approved to treat in this label?
The selected Celexa label lists major depressive disorder in adults, not an anxiety-disorder indication. Understanding the exact medicine name and formulation and the purpose of serious-risk patient information helps keep that statement attached to the correct product.
Celexa is the brand name; citalopram hydrobromide is its active ingredient. This record concerns tablets for oral use. Its indication establishes a labeled use, not the reason any particular person received a prescription. An anxiety-related prescription cannot be judged from this indication statement alone.
The label classifies citalopram as a selective serotonin reuptake inhibitor, or SSRI. Its proposed antidepressant action involves reducing nerve-cell reuptake of serotonin, affecting serotonin activity in the central nervous system. However, the label explicitly describes the antidepressant mechanism as unclear. That is not evidence that an individual’s depression results from a demonstrated serotonin deficiency. See sections 1 and 12.1 of the selected FDA Celexa record.
Why does Celexa carry a heart-rhythm warning?
The label describes a dose-dependent effect on QTc, a measurement of the heart’s electrical timing. This is a product-specific concern, not simply a general antidepressant warning. MVBH’s explanations of serious-risk language and professional medicine information provide context without interpreting anyone’s heart tracing.
QTc is assessed on an electrocardiogram, or ECG. A prolonged measurement is not itself the same as a diagnosed dangerous rhythm. It matters because QTc prolongation is associated with serious rhythm disturbances. The label names torsade de pointes and ventricular tachycardia, and reports of sudden death. “Dose-dependent” describes how the measured effect relates to dose; it is not a basis for calculating personal safety from an article.
Exposure also matters. Here, exposure means how much medicine the body encounters over time, not merely the amount printed on a prescription. The label identifies higher exposure in older adults and people with hepatic impairment, meaning impaired liver function. It also identifies CYP2C19 poor-metabolizer status and medicines that inhibit CYP2C19 as exposure-related concerns.
CYP2C19 is an enzyme involved in processing medicines. Poor-metabolizer status describes reduced activity in that pathway; an inhibiting medicine can also affect the pathway. These circumstances help explain why prescribing decisions may differ between adults. They are not instructions for changing a prescription or a recommendation for genetic testing.
The warning also addresses certain heart conditions and low potassium or magnesium. Its electrolyte and ECG monitoring language applies to specified circumstances, including significant electrolyte-disturbance risk or particular cardiac and medication-related concerns. It does not establish one identical testing plan for every adult. These details appear in sections 5.2, 8.5, and 8.6 of the selected label.
The label directs immediate professional attention for feeling faint, losing consciousness, or having heart palpitations. Do not dismiss these symptoms as anxiety or wait for a routine mental health appointment. Call 911 for immediate danger or a life-threatening emergency. The cardiac symptom guidance appears in section 17 of the Celexa record.
Which side effects does the selected Celexa label describe?
The label reports gastrointestinal, sleep-related, and sexual adverse reactions, among others. These observations answer a different question from a serious warning. The distinction is explained in MVBH’s resources on medicine information documents and serious medication risks.
- Digestive effects include nausea, diarrhea, and indigestion.
- Dry mouth and increased sweating appear in the trial-reported reactions.
- Both sleepiness and insomnia were reported, so the label does not describe only one possible sleep effect.
- Sexual effects include delayed ejaculation, reduced desire, erection difficulties, and delayed or absent orgasm.
Sexual effects deserve particular context. The label explains that people and clinicians may be reluctant to discuss sexual functioning, so reported rates may underestimate actual occurrence. At the same time, psychiatric symptoms can affect desire, performance, and satisfaction. A change therefore matters without automatically proving a medication cause.
The trial tables describe observations in defined study groups. They do not say everyone experiences these effects, that an unlisted symptom is impossible, or that a familiar symptom is harmless in every situation. Sections 6.1 and 5.10 of the selected Celexa label support these distinctions.
How do citalopram’s labeled interactions differ?
The interactions concern several different processes: electrical timing, medicine exposure, serotonin effects, and bleeding. Matching the interaction information to the product and retaining the context of serious warnings prevents treating every interaction as the same problem.
The following comparison explains interaction categories in sections 4, 5, and 7 of the selected FDA record. It is not a combination checker or safety ranking.
| Interaction concern | What the label describes | What this does not establish |
|---|---|---|
| Additional QT effects | Other QT-prolonging medicines can add to the electrical-timing effect. | Whether a particular combination is appropriate for an individual. |
| CYP2C19 inhibition | Reduced processing can increase citalopram exposure and cardiac concerns. | A personal prescription adjustment or genetic-testing need. |
| Serotonergic combinations | Other serotonin-affecting drugs can increase serotonin-syndrome risk. | That every symptom during combined treatment is serotonin syndrome. |
| Bleeding-related combinations | Antiplatelet medicines and anticoagulants can add to bleeding risk. | A safe-combination list or an individual bleeding prediction. |
- Pimozide is explicitly contraindicated with Celexa because of cardiac rhythm concerns; the label also describes increased pimozide concentrations.
- Monoamine oxidase inhibitors, or MAOIs, are contraindicated because of serotonin-syndrome risk. This includes certain nonpsychiatric medicines, such as linezolid.
- Other serotonergic products named in the label include lithium, tramadol, buspirone, and St. John’s wort. A supplement can therefore be relevant to interaction review.
- Aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet medicines, and anticoagulants appear in the bleeding warning.
“Contraindicated” marks a professional prescribing boundary, not merely a frequently reported side effect. These examples are not exhaustive and cannot clear a medication combination for use.
What do the mood and suicide warnings mean for adults?
The boxed warning identifies increased suicidal thoughts and behaviors in young adults in short-term antidepressant studies, while calling for attention to worsening symptoms across adult ages. Both the purpose of serious-risk information and the limits of general medicine summaries matter when interpreting that distinction.
The label’s pooled findings identify the young-adult group as ages 18 through 24. They do not establish identical risk at every age. New suicidal thoughts, unusual behavior changes, or worsening depression still require prompt attention in treated adults of any age. See the boxed warning and section 5.1 of the selected label.
A separate warning concerns activation of mania or hypomania. The label describes possible activation in people with bipolar disorder and the relevance of personal and family mood history. Markedly increased activity, racing thoughts, or unusual behavior changes need clinical attention, but do not establish a diagnosis by themselves. See section 5.5 and the Medication Guide in the selected Celexa record.
Call or text 988 for suicide or crisis support. Call 911 for immediate danger or a life-threatening emergency, as described by NIMH. MVBH is not emergency care.
What other serious warnings need a separate explanation?
Serotonin syndrome and low blood sodium are different potentially serious conditions, not interchangeable names for ordinary side effects. MVBH’s guides to serious warning information and full prescribing information explain why each warning needs its own context.
Serotonin syndrome can involve changes in mental state, temperature, heart rate, and muscle activity. Examples in the label include confusion, high temperature, tremor, and muscle rigidity. It can occur with Celexa alone, although certain combinations increase risk. Suspected symptoms require immediate medical attention, not home diagnosis.
Hyponatremia means low sodium in the blood. The label describes possible headache, confusion, weakness, and unsteadiness; severe cases can include seizures or loss of consciousness. Older adults and certain other groups may have greater risk. For possible low-sodium symptoms, the Medication Guide calls for contacting a health care professional right away. These symptoms cannot confirm low sodium without medical evaluation. See section 5.9 and the Medication Guide in the selected Celexa record. Call 911 for immediate danger or life-threatening symptoms.
Additional warnings concern seizures, angle-closure glaucoma, and hypersensitivity reactions. Eye pain or vision changes warrant prompt medical attention. The label also describes discontinuation reactions, including dizziness, sensory disturbances, and mood changes, particularly after abrupt discontinuation. This article provides no stopping or tapering plan. These warnings appear in sections 4 and 5 of the selected Celexa record.
What can this label not tell you about personal benefit?
A labeled indication does not predict personal benefit, and an adverse-event listing does not prove what caused your symptom. MVBH’s resources on interpreting serious risks and understanding medicine documents support that boundary without replacing an individual treatment discussion.
Trial participants, study conditions, and reporting methods affect adverse-reaction tables. The label cautions against directly comparing rates across different drug trials or assuming those rates match everyday practice. Voluntary postmarketing reports have another limitation: the population size is uncertain, so frequency and causation may not be reliably established. This record’s postmarketing section also combines citalopram and escitalopram reports, rather than establishing citalopram-specific rates. See section 6 of the selected record.
The supplied extract does not support an effectiveness or response-timeline summary. More broadly, NIMH explains that treatment planning depends on individual needs and medical circumstances, and psychotherapy may accompany medication. Product information contributes evidence to that process; it cannot complete it.
Written by Tim Francis, SUD Content Specialist. This article is educational and does not provide individual prescribing advice.
Frequently asked questions
Does this Celexa label include an anxiety-disorder indication?
No. Section 1 of the selected Celexa label lists major depressive disorder in adults. That statement describes this product’s labeled indication. It does not establish why an individual received a prescription, judge that prescription, or establish the indications of every other citalopram product.
Does QTc prolongation mean someone already has a dangerous rhythm?
No. QTc is an ECG measurement of electrical timing, not the same thing as a diagnosed dangerous rhythm. The selected label connects prolongation with potentially serious rhythm disturbances. It directs immediate professional attention for feeling faint, losing consciousness, or heart palpitations. An article cannot interpret an individual ECG.
Does everyone reading this label need the same heart tests?
No. The Celexa warning describes electrolyte and ECG monitoring in specified circumstances, including particular electrolyte, cardiac, and medication-related concerns. It does not prescribe an identical testing plan for every adult. This article neither selects a monitoring plan nor establishes that MVBH provides ECGs or electrolyte testing.
Why might the sexual-side-effect figures be incomplete?
The selected label explains that reluctance to discuss sexual functioning can lead to underreporting. It also notes that psychiatric conditions can affect sexual desire, performance, and satisfaction. Reported figures therefore cannot capture every experience or identify the cause of an individual change. The concern remains relevant even when its cause is uncertain.
Can postmarketing reports show how likely a reaction is for me?
Not reliably. The label’s postmarketing section describes voluntary reports from a population of uncertain size, which limits frequency estimates and causal conclusions. It also includes reports associated with citalopram or escitalopram. That combined list cannot establish a citalopram-specific incidence, predict your experience, or prove the cause of a symptom.
